Literature DB >> 8542424

CNS tumor therapy by attenuated herpes simplex viruses.

T Mineta1, J M Markert, Y Takamiya, D M Coen, S D Rabkin, R L Martuza.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 8542424

Source DB:  PubMed          Journal:  Gene Ther        ISSN： 0969-7128            Impact factor:   5.250


× No keyword cloud information.
  6 in total

Review 1.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 2.  Herpes simplex viruses: is a vaccine tenable?

Authors:  Richard J Whitley; Bernard Roizman
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

3.  Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.

Authors:  J N Parker; G Y Gillespie; C E Love; S Randall; R J Whitley; J M Markert
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

4.  Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment.

Authors:  L J Ausubel; M Meseck; I Derecho; P Lopez; C Knoblauch; R McMahon; J Anderson; N Dunphy; V Quezada; R Khan; P Huang; W Dang; M Luo; D Hsu; S L C Woo; L Couture
Journal:  Hum Gene Ther       Date:  2011-03-08       Impact factor: 5.695

5.  Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.

Authors:  James M Markert; Peter G Liechty; Wenquan Wang; Shanna Gaston; Eunice Braz; Matthias Karrasch; Louis B Nabors; Michael Markiewicz; Alfred D Lakeman; Cheryl A Palmer; Jacqueline N Parker; Richard J Whitley; George Y Gillespie
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

6.  A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.

Authors:  James M Markert; Shantanu N Razdan; Hui-Chien Kuo; Alan Cantor; Anette Knoll; Matthias Karrasch; L Burt Nabors; Michael Markiewicz; Bonita S Agee; Jennifer M Coleman; Alfred D Lakeman; Cheryl A Palmer; Jacqueline N Parker; Richard J Whitley; Ralph R Weichselbaum; John B Fiveash; G Yancey Gillespie
Journal:  Mol Ther       Date:  2014-02-27       Impact factor: 11.454
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.